-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)Drug Details:Plogosertib is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Bladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Bladder Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Diffuse Large B-Cell Lymphoma Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Pancreatic Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Non-Small Cell Lung Cancer Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Lymphoma Drug Details:Plogosertib is under development for the treatment of solid tumors including triple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Myelodysplastic Syndrome Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Small-Cell Lung Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Solid Tumor Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Peripheral T-Cell Lymphomas (PTCL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Peripheral T-Cell Lymphomas (PTCL) Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Esophageal Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Triple-Negative Breast Cancer (TNBC) Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Cutaneous T-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Cutaneous T-Cell Lymphoma Drug Details:Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Ovarian Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Relapsed Acute Myeloid Leukemia Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Colorectal Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Gallbladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Gallbladder Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Biliary Tract Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Biliary Tract Cancer Drug Details:Plogosertib is under development for the treatment of solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.